Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.

Mary Ann Anderson,Matthew S. Davids,Arnon P. Kater,Tara Cochrane,Fatih Demirkan,Yair Herishanu,Brian Leber,E. A. Nikitin,Abdullah Masud,Tanya S. Rosenberg,Simon Sharmokh,Stan Fort,Francesco Forconi

Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.

2020

Mary Ann Anderson
Matthew S. Davids
Arnon P. Kater
Tara Cochrane
Fatih Demirkan
Yair Herishanu
Brian Leber
E. A. Nikitin
Abdullah Masud
Tanya S. Rosenberg
Simon Sharmokh
Stan Fort
Francesco Forconi

e20011Background: Neutropenia is a common hematologic Grade (Gr) 3+ adverse event (AE) recorded in patients with chronic lymphocytic leukemia (CLL) receiving venetoclax (VEN). In this analysis, we ...

Keywords:

Venetoclax
Oncology
in patient
Refractory Chronic Lymphocytic Leukemia
pooled data
Pathology
Internal medicine
Medicine
Neutropenia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations